Risultati per: È confermato il legame tra la malattia di Alzheimer e microbiota intestinale
Questo è quello che abbiamo trovato per te
Fecal microbiota transplantation for recurrent C. difficile infection can be the best therapeutic option in severely immunocompromised patients depending on a case-by-case assessment of the benefit/risk ratio
Patricia Lorusso (Aacr), 'Il tumore diventerà una malattia cronica a lunga sopravvivenza e buona qualità di vita'
La presidente dell’Associazione americana ricerca sul cancro, ‘vedremo grandi cambiamenti’
A Cesena il primo “giardino Alzheimer” d'Italia
Sorgerà all’interno di un parco pubblico
Spallanzani, tenere alta attenzione su malattia tropicale Chagas
Giornata mondiale. All’Inmi test per chi viene da America latina
L'Ictus malattia anche dei giovani, colpiti 12mila under 55 l'anno
Al via Congresso,test su popolazione insieme alla GdF a L’Aquila
Scoperto un gene che riduce il rischio di Alzheimer fino al 70%
La mutazione aumenta l’abilità del cervello di ripulirsi
Mixed-donor faecal microbiota transplantation was associated with increased butyrate-producing bacteria for obesity
We read with interest the recent article by Haifer et al (Gut, 2022, 2022–3 27 742), which reported that donor gut microbiome stability and species evenness were associated with higher donor species engraftment in patients with UC following faecal microbiota transplantation (FMT). This has brought us one step closer towards the selection of optimal FMT donors. However, the high prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic have restricted the recruitment of FMT donors.1 An alternative means to increase the stability and species evenness is to pool the stool samples from multiple eligible FMT donors, which has been shown to be associated with higher clinical efficacy in UC.2 In obesity-related metabolic disorders, outcomes following FMT have been variable.3–8 Although the underlying mechanisms are unclear, the efficacy of FMT is likely to be affected by…
Levels of Spinal Fluid Amyloid Become Abnormal Long Before Alzheimer Disease Is Clinically Apparent
This finding strengthens the case for early targeting of amyloid-β42 in people at excess risk for AD.
Allerta in Giappone per una rara infezione, “malattia carnivora”
Per le preoccupazioni la Corea del Nord avrebbe cancellato una partita
Identificato un nuovo target terapeutico per la malattia di Alzheimer
Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis
Variations in several biomarkers, including proteins found in cerebrospinal fluid (CSF), might appear 6 to 18 years before a person develops Alzheimer disease, according to a prospective cohort study that included more than 600 participants in China with no family history of the condition.
Alzheimer’s Disease — Managing Stages of Dementia
New England Journal of Medicine, Volume 390, Issue 12, March 2024.
Ok degli Usa alla terapia genica ideata in Italia per una malattia rara
Trattamento messo a punto dall’Istituto San Raffaele Telethon
Covid: Girardi, oggi la malattia è totalmente diversa
Direttore scientifico Spallanzani, importante vaccinare fragili